Loss of Y chromosome and  cardiovascular events in chronic kidney disease

Sebastian Cremer (Frankfurt am Main)1, M. Weyrich (Frankfurt am Main)2, M. Gerster (Frankfurt am Main)2, T. Sarakpi (Frankfurt am Main)2, T. Rasper (Frankfurt am Main)2, G. Heine (Frankfurt am Main)3, C. Wanner (Würzburg)4, A. Merz (Berlin)5, W. März (Eppelheim)6, D. Fliser (Homburg/Saar)7, S. Dimmeler (Frankfurt am Main)8, A. M. Zeiher (Frankfurt am Main)9, T. Speer (Frankfurt am Main)2

1Universitätsklinikum Frankfurt Med. Klinik III - Kardiologie, Angiologie Frankfurt am Main, Deutschland; 2Universitätsklinikum Frankfurt Frankfurt am Main, Deutschland; 3Agaplesion Markus Krankenhaus Frankfurt am Main, Deutschland; 4Universitätsklinikum Würzburg Medizinische Klinik und Poliklinik II Würzburg, Deutschland; 5Charité - Universitätsmedizin Berlin Berlin, Deutschland; 6Synlab Medizinisches Versorgungszentrum Heidelberg GmbH Eppelheim, Deutschland; 7Universitätsklinikum des Saarlandes Homburg/Saar, Deutschland; 8Goethe Universität Frankfurt am Main Zentrum für Molekulare Medizin, Institut für Kardiovaskuläre Regeneration Frankfurt am Main, Deutschland; 9Goethe Universität Frankfurt am Main Institute of Cardiovascular Regeneration Frankfurt am Main, Deutschland



Chronic kidney disease represents one of the strongest risk factors for cardiovascular diseases, and particularly for heart failure. Despite improved pharmaceutical treatments mortality remains high. Recently, mosaic loss of Y chromosome (LOY) emerged as an important driver of cardiac fibrosis in men. We determined the effects of LOY on mortality and cardiovascular disease outcomes in patients with chronic kidney disease.


LOY was quantified in patients with stable CKD (CARE for HOMe study, derivation cohort, N=279) and dialysis patients (4D study, validation cohort, N=544). The association between LOY and mortality, combined cardiovascular and heart failure-specific endpoints, and echocardiographic measures was assessed. 


In CARE for HOMe, mortality was higher in men as compared to women across the entire range of impaired renal function. The frequency of LOY increased with age. LOY was associated with increased mortality (HR 2.90, 95%CI 1.50-5.60) and risk for cardiac decompensation and death (HR 2.54, 95%CI 1.37-4.69). Patients with LOY >17 % had higher NT-proBNP, troponin-T levels, and worse diastolic and systolic left ventricular function Consistently, validation in the 4D study revealed that LOY was associated with increased cardiovascular mortality (HR 3.00, 95%CI 1.89-4.78), higher risk of death due to heart failure and sudden cardiac death (HR 3.91, 95%CI 1.89-8.07), but not atherosclerotic events. Mechanistically, intermediate monocytes from patients with LOY >17 % showed significantly higher CCR2 expression, which may have contributed to increased heart failure events.


LOY identifies male patients with chronic kidney disease at high risk for mortality and heart failure events. 

Diese Seite teilen